blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2252148

EP2252148 - METHODS FOR TREATING IRRITABLE BOWEL SYNDROME [Right-click to bookmark this link]
Former [2010/47]METHODS FOR TREATING BOWEL DISEASES
[2018/41]
StatusPatent revoked
Status updated on  25.10.2024
Database last updated on 03.04.2025
FormerThe patent has been granted
Status updated on  15.02.2019
FormerGrant of patent is intended
Status updated on  03.10.2018
FormerExamination is in progress
Status updated on  23.12.2016
Most recent event   Tooltip25.10.2024Revocation of patentpublished on 27.11.2024  [2024/48]
Applicant(s)For all designated states
Salix Pharmaceuticals, Inc.
8450 Colonnade Center Drive
Raleigh, NC 27615 / US
[2023/31]
Former [2010/47]For all designated states
Salix Pharmaceuticals, Ltd.
1700 Perimeter Park Drive
Morrisville, NC 27560 / US
Inventor(s)01 / FORBES, William
1008 Heydon Court
Raleigh NC 27614 / US
02 / JOHNSON, Lorin
195-A Bryant Street
Palo Alto CA 94301 / US
 [2010/47]
Representative(s)Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[N/P]
Former [2019/12]Adam, Holger, et al
Kraus & Weisert
Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
Former [2010/47]Adam, Holger, et al
Kraus & Weisert Patent- und Rechtsanwälte Thomas-Wimmer-Ring 15
80539 München / DE
Application number, filing date09715020.526.02.2009
[2010/47]
WO2009US35348
Priority number, dateUS20080031679P26.02.2008         Original published format: US 31679 P
US20080102801P03.10.2008         Original published format: US 102801 P
[2010/47]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009108814
Date:03.09.2009
Language:EN
[2009/36]
Type: A1 Application with search report 
No.:EP2252148
Date:24.11.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 03.09.2009 takes the place of the publication of the European patent application.
[2010/47]
Type: B1 Patent specification 
No.:EP2252148
Date:20.03.2019
Language:EN
[2019/12]
Search report(s)International search report - published on:US03.09.2009
(Supplementary) European search report - dispatched on:EP23.01.2014
ClassificationIPC:A61K31/437, // A61P1/00, A61P31/00
[2018/41]
CPC:
A61K31/437 (EP,KR,US); A61K31/395 (EP,KR,US); A61K31/4184 (KR);
A61P1/00 (EP,KR,US); C12Q1/6883 (KR); C12Q2600/156 (KR)
Former IPC [2014/08]A61K31/395, A61K31/4184, // A61P1/00, A61P31/00
Former IPC [2010/47]A01N43/40
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2019/12]
Former [2010/47]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL27.09.2010
BA27.09.2010
RS27.09.2010
TitleGerman:VERFAHREN ZUR BEHANDLUNG VON REIZDARMSYNDROM[2018/41]
English:METHODS FOR TREATING IRRITABLE BOWEL SYNDROME[2018/41]
French:MÉTHODES DE TRAITEMENT DU SYNDROME DE L'INTESTIN IRRITABLE[2018/41]
Former [2010/47]VERFAHREN ZUR BEHANDLUNG VON DARMERKRANKUNGEN
Former [2010/47]METHODS FOR TREATING BOWEL DISEASES
Former [2010/47]MÉTHODES DE TRAITEMENT DE MALADIES ENTÉRIQUES
Entry into regional phase08.09.2010National basic fee paid 
08.09.2010Search fee paid 
08.09.2010Designation fee(s) paid 
08.09.2010Examination fee paid 
Examination procedure08.09.2010Examination requested  [2010/47]
11.08.2014Amendment by applicant (claims and/or description)
02.01.2017Despatch of a communication from the examining division (Time limit: M04)
08.05.2017Reply to a communication from the examining division
19.03.2018Despatch of a communication from the examining division (Time limit: M04)
25.06.2018Reply to a communication from the examining division
04.10.2018Communication of intention to grant the patent
10.01.2019Fee for grant paid
10.01.2019Fee for publishing/printing paid
10.01.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19163419.5  / EP3563850
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  02.01.2017
Opposition(s)Opponent(s)01  18.12.2019  20.12.2019  ADMISSIBLE
Sandoz GmbH
Biochemiestrasse 10
6250 Kundl / AT
Opponent's representative
Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 02  19.12.2019  07.01.2020  ADMISSIBLE
Kraus & Lederer PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
Opponent's representative
Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 03  19.12.2019  07.01.2020  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
D Young & Co LLP
3 Noble Street
London EC2V 7BQ / GB
 [N/P]
Former [2024/10]
Opponent(s)01  18.12.2019  20.12.2019  ADMISSIBLE
Sandoz GmbH
Biochemiestrasse 10
6250 Kundl / AT
Opponent's representative
Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 02  19.12.2019  07.01.2020  ADMISSIBLE
Kraus & Lederer PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
Opponent's representative
Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 03  19.12.2019  07.01.2020  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Former [2024/08]
Opponent(s)01  18.12.2019  20.12.2019  ADMISSIBLE
Sandoz GmbH
Biochemiestrasse 10
6250 Kundl / AT
Opponent's representative
Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 02  19.12.2019  07.01.2020  ADMISSIBLE
Kraus & Lederer PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
Opponent's representative
Kraus & Lederer PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
 03  19.12.2019  07.01.2020  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Former [2024/04]
Opponent(s)01  18.12.2019  20.12.2019  ADMISSIBLE
Sandoz GmbH
Biochemiestrasse 10
6250 Kundl / AT
Opponent's representative
Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 02  19.12.2019  07.01.2020  ADMISSIBLE
Kraus & Weisert Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
Opponent's representative
Kraus & Weisert Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
 03  19.12.2019  07.01.2020  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Former [2022/09]
Opponent(s)01  18.12.2019  20.12.2019  ADMISSIBLE
Sandoz GmbH
Biochemiestrasse 10
6250 Kundl / AT
Opponent's representative
Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 02  19.12.2019  07.01.2020  ADMISSIBLE
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstr. 2
80538 München / DE
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 03  19.12.2019  07.01.2020  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Former [2020/05]
Opponent(s)01  18.12.2019  20.12.2019  ADMISSIBLE
Sandoz GmbH
Biochemiestrasse 10
6250 Kundl / AT
Opponent's representative
Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 02  19.12.2019    ADMISSIBLE
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstr. 2
80538 München / DE
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 03  19.12.2019    ADMISSIBLE
Teva Pharmaceutical Industries Ltd
5 Basel Street
P.O. Box 3190
49131 Petah Tiqva / IL
Opponent's representative
D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Former [2020/04]
Opponent(s)01  18.12.2019    ADMISSIBLE
Sandoz GmbH
Biochemiestrasse 10
6250 Kundl / AT
Opponent's representative
Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 02  19.12.2019   
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstr. 2
80538 München / DE
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
20.01.2020Invitation to proprietor to file observations on the notice of opposition
29.07.2020Reply of patent proprietor to notice(s) of opposition
30.09.2021Date of oral proceedings
09.11.2021Despatch of minutes of oral proceedings
09.11.2021Despatch of communication that the patent will be revoked
09.10.2024Legal effect of revocation of patent [2024/48]
Appeal following opposition07.01.2022Appeal received No.  T0162/22
07.01.2022Payment of appeal fee
18.03.2022Statement of grounds filed
09.10.2024Result of appeal procedure: appeal of the proprietor was rejected
17.10.2024Despatch of the decision of the Board of Appeal
09.10.2024Date of oral proceedings
Fees paidRenewal fee
23.02.2011Renewal fee patent year 03
24.02.2012Renewal fee patent year 04
27.02.2013Renewal fee patent year 05
27.02.2014Renewal fee patent year 06
26.02.2015Renewal fee patent year 07
08.02.2016Renewal fee patent year 08
07.02.2017Renewal fee patent year 09
07.02.2018Renewal fee patent year 10
08.02.2019Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU26.02.2009
CY20.03.2019
CZ20.03.2019
EE20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
MC20.03.2019
MK20.03.2019
MT20.03.2019
RO20.03.2019
SI20.03.2019
SK20.03.2019
TR20.03.2019
BG20.06.2019
GR21.06.2019
IS20.07.2019
[2022/32]
Former [2022/30]HU26.02.2009
CY20.03.2019
CZ20.03.2019
EE20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
MC20.03.2019
MT20.03.2019
RO20.03.2019
SI20.03.2019
SK20.03.2019
TR20.03.2019
BG20.06.2019
GR21.06.2019
IS20.07.2019
Former [2022/27]HU26.02.2009
CY20.03.2019
CZ20.03.2019
EE20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
MC20.03.2019
MT20.03.2019
RO20.03.2019
SI20.03.2019
SK20.03.2019
TR20.03.2019
BG20.06.2019
GR21.06.2019
IS20.07.2019
PT20.07.2019
Former [2020/49]CZ20.03.2019
EE20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
MC20.03.2019
RO20.03.2019
SI20.03.2019
SK20.03.2019
TR20.03.2019
BG20.06.2019
GR21.06.2019
IS20.07.2019
PT20.07.2019
Former [2020/17]CZ20.03.2019
EE20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
RO20.03.2019
SI20.03.2019
SK20.03.2019
TR20.03.2019
BG20.06.2019
GR21.06.2019
IS20.07.2019
PT20.07.2019
Former [2020/13]CZ20.03.2019
EE20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
RO20.03.2019
SI20.03.2019
SK20.03.2019
BG20.06.2019
GR21.06.2019
IS20.07.2019
PT20.07.2019
Former [2020/04]CZ20.03.2019
EE20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
RO20.03.2019
SK20.03.2019
BG20.06.2019
GR21.06.2019
IS20.07.2019
PT20.07.2019
Former [2019/49]CZ20.03.2019
EE20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
RO20.03.2019
SK20.03.2019
BG20.06.2019
GR21.06.2019
PT20.07.2019
Former [2019/48]HR20.03.2019
LT20.03.2019
LV20.03.2019
BG20.06.2019
GR21.06.2019
PT20.07.2019
Former [2019/39]HR20.03.2019
LT20.03.2019
LV20.03.2019
BG20.06.2019
GR21.06.2019
Former [2019/38]LT20.03.2019
BG20.06.2019
GR21.06.2019
Former [2019/37]LT20.03.2019
GR21.06.2019
Former [2019/33]LT20.03.2019
Documents cited:Search[XI]  - PIMENTEL MARK ET AL, "A 10-day course of rifaximin, a non-absorbable antibiotic, produces a durable improvement in all symptoms of irritable bowel syndrome: A double-blind randomized controlled study", GASTROENTEROLOGY, & DIGESTIVE DISEASE WEEK MEETING/107TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; LOS ANGELES, CA, USA; MAY 19 -24, 2006, (200604), vol. 130, no. 4, Suppl. 2, ISSN 0016-5085, page A26, XP002718616 [X] 1,2,5,7-12 * abstract * [I] 6,13
 [XI]  - FRISSORA C L ET AL, "Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome.", ALIMENTARY PHARMACOLOGY & THERAPEUTICS 1 JUN 2007, (20070601), vol. 25, no. 11, ISSN 0269-2813, pages 1271 - 1281, XP002718617 [X] 1,2,5,9-12 * page 1278 - page 1279; figure 1 * [I] 6,13

DOI:   http://dx.doi.org/10.1111/j.1365-2036.2007.03313.x
 [X]  - Raleigh, N.C., "Rifaximin Demonstrates Statistically Significant Improvement in Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable Bowel Syndrome in Phase IIb Study", (200709), www.drugs.com, URL: http://www.drugs.com/clinical_trials/rifaximin-demonstrates-statistically-significant-improvement-co-primary-endpoints-diarrhea-1851.html?printable=1, (20140113), XP002718618 [X] 1,2,5-12 * abstract *
 [X]  - STEFFEN ROBERT ET AL, "Therapy of travelers' diarrhea with rifaximin on various continents.", THE AMERICAN JOURNAL OF GASTROENTEROLOGY MAY 2003, (200305), vol. 98, no. 5, ISSN 0002-9270, pages 1073 - 1078, XP002718619 [X] 1,5,7,10-12 * abstract * * figure 1 *

DOI:   http://dx.doi.org/10.1111/j.1572-0241.2003.07283.x
 [X]  - BASS N M, "Review article: the current pharmacological therapies for hepatic encephalopathy", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, BLACKWELL SCIENTIFIC PUBLICATIONS LTD., CAMBRIDGE, GB, vol. 25, no. SUPPL 1, doi:10.1111/J.1746-6342.2006.03218.X, ISSN 0269-2813, (20070201), pages 23 - 31, (20070123), XP002669397 [X] 1,3-5,7,10-12 * page 25, column r - page 28, column l *

DOI:   http://dx.doi.org/10.1111/J.1746-6342.2006.03218.X
 [X]  - E. SCARPELLINI ET AL, "High dosage rifaximin for the treatment of small intestinal bacterial overgrowth", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, (20070401), vol. 25, no. 7, doi:10.1111/j.1365-2036.2007.03259.x, ISSN 0269-2813, pages 781 - 786, XP055046220 [X] 1,2,5,7,10-12 * the whole document *

DOI:   http://dx.doi.org/10.1111/j.1365-2036.2007.03259.x
International search[Y]US2005272754  (VISCOMI GIUSEPPE C [IT], et al);
 [Y]WO2006094737  (ALFA WASSERMANN SPA [IT], et al);
 [Y]WO2007064964  (PROMETHEUS LAB INC [US], et al);
 [Y]US2007259906  (CARAS STEVEN D [US]);
by applicantEP0161534
 IT1154655
 US7045620
 WO2006094662
 US20080962208
 US20080963008
 US20080961208
 US20080960008
 EP20050004635
 US20070658702
 US20070873841
 US20080031329
 US20090393012
OppositionWO2009108814
    - ADACHI, J.A. et al., "Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders", Clinical Infectious Diseases, (20060000), vol. 42, no. 4, pages 541 - 547, XP008103995
    - SAAD, R.J. et al., "Recent developments in the therapy of irritable bowel syndrome", Exp Opin Investigat Drugs, (20080000), vol. 17, no. 2, pages 117 - 130, XP002636021

DOI:   http://dx.doi.org/10.1517/13543784.17.2.117
    - PIMENTEL, M., "Bacteria and the role of antibiotics in irritable bowel syndrome", Practical Gastroenterology, (20070000), vol. 31, no. 9, pages 25 - 32, XP055662587
    - PIMENTEL, M. et al., "A 10-day course of rifaximin, a non-absorbable antibiotic, produces a durable improvement in all symtoms of irritable bowel syndrome: a double-blind randomized controlled study", Gastroenterology, (20060000), vol. 130, no. 4, page A-26, XP055662591
    - PIMENTEL, M. et al., "The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome", Ann Intern Med, (20060000), vol. 145, no. 8, pages 557 - 563, XP008140626
    - Raleigh; N C, "Rifaximin Demonstrates Statistically Significant Improvement in Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable Bowel Syndrome in Phase IIb Study", www.drugs.com, (20070905), page 1, XP002718618
    - Anonymous, "Salix presents new rifaximin phase IIB data demonstrating significant and sustained improvement in diarrhea- associated irritable bowel syndrome (D-IBS)", Press release, (20080520), pages 1 - 3, XP055662597
    - Raleigh N. C., "Salix initiates phase 3 for rifaximin in non-constipation irritable bowel syndrome", Press release, (20080630), pages 1 - 3, XP055662601
    - Anonymous, "History of changes for study:NCT00269412, study assess the efficacy and safety of rifaximin administered BID in the treatment of patients with diarrhea-associated irritable bowel syndrome", Clinical Trial, pages 1 - 10, XP055662611
    - SCARPELLINI, E. et al., "High dosage rifaximin for the treatment of small intestinal bacterial overgrowth", Alimentary Pharmacology and Therapeutics, (20070000), vol. 25, no. 7, pages 781 - 786, XP055046220

DOI:   http://dx.doi.org/10.1111/j.1365-2036.2007.03259.x
    - PIMENTEL M et al., "A 10-day course of rifaximin, a non-absorbable antibiotic, produces a durable improvement in all symtoms of irritable bowel syndrome: a double-blind randomized controlled study", Gastroenterolog y, (20060000), vol. 130, no. 4, page A26, XP055662591
    - FRISSORA C et al., "Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome", Alimentary Pharmacology & Therapeutics, (20070000), vol. 25, no. 11, pages 1271 - 1281, XP002718617

DOI:   http://dx.doi.org/10.1111/j.1365-2036.2007.03313.x
    - "Rifaximin Demonstrates Statistically Significant Improvement in Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable Bowel Syndrome in Phase Ilb Study", Press Release (Business Wire, (20070905), XP002718618
    - SCARPELLINI E et al., "High dosage rifaximin for the treatment of small intestinal bacterial overgrowt", Alimentary Pharmacology & Therapeutics, (20070000), vol. 25, pages 781 - 786, XP055046220

DOI:   http://dx.doi.org/10.1111/j.1365-2036.2007.03259.x
    - PIMENTEL M et al., "The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome", Annals of Internal Medicine, (20060000), vol. 145, no. 8, pages 555 - 563, XP008140626
    - SHARARA A et al., "A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in Patients with Abdominal Bloating and Flatulence", Am J Gastroenterology, (20060000), vol. 101, pages 326 - 333, XP008140619

DOI:   http://dx.doi.org/10.1111/J.1572-0241.2006.00458.X
    - LAURITANO E et al., "Association between Hypothyroidism and Small Intestinal Bacterial Overgrowth", J Clin Endocrinology & Metabolism, (20070000), vol. 92, no. 11, pages 4180 - 4184, XP008140625

DOI:   http://dx.doi.org/10.1210/jc.2007-06064180
    - "Rifaximin (XIFAXAN) for irritable bowel syndrome with diarrhea", national drug monograph, (20160300), XP055671171
    - LEMBO et al., Abstract T1390 Gastroenterology, (20080400), vol. 134, no. 4, page A-545
    - RINGEL et al., Abstract T1411 Gastroenterology, (20080400), vol. 134, no. 4, page A-550
    - Protocol of clinical trial NCT00269412, (20071206), URL: www.clinicaltrials.gov, XP055671744
    - "Rifaximin Demonstrates Statistically Significant Improvement in Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable Bowel Syndrome in Phase lib Study", WWW.DRUGS.COM, (20070905), XP002718618
    - PIMENTEL, M et al., "The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome", Annals Int. Med., (20060000), vol. 145, no. 8, pages 557 - 563, XP008140626
    - FRISSORA, C.L. et al., "Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome", Aliment. Pharmacol. Ther., (20070000), vol. 25, pages 1271 - 1281, XP002718617

DOI:   http://dx.doi.org/10.1111/j.1365-2036.2007.03313.x
    - SCARPELLINI, E. et al., "High dosage rifaximin for the treatment of small intestinal bacterial overgrowt", Aliment. Pharmacol. Ther., (20070000), vol. 25, pages 781 - 786, XP055046220

DOI:   http://dx.doi.org/10.1111/j.1365-2036.2007.03259.x
    - SHARARA, A.I. et al., "A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in Patients with Abdominal Bloating and Flatulence", Am. J. Gastroenterol., (20060000), vol. 101, pages 326 - 333, XP008140619

DOI:   http://dx.doi.org/10.1111/J.1572-0241.2006.00458.X
    - POTTER, J. E. R. et al., "Past versus present: the importance of tense in patent application examples", Nat. Biotechnol., (20030000), vol. 21, no. 3, pages 1397 - 1398, XP055020529

DOI:   http://dx.doi.org/10.1038/nbt1103-1397
    - Protocol of clinical trial NCT00724126, (20090119), URL: www.clinicaltrials.gov
    - "Salix Presents New Phase II Data Evidence Demonstrating the Clinical Utility of Rifaximin in Irritable Bowel Syndrome (IBS", PRESS RELEASE, (20081006), XP055662597
    - LEMBO, A et al., Gastroenterology, (20080400), vol. 134, no. 4
    - PIMENTEL, M et al., "Severity of Irritable Bowel Syndrom related Symptoms Predicts Clinical response to the nonsystemic antibiotic rifaximin", Am. J. Gastroenterology, (20080900), vol. 103, XP055671764
    - CHEY, W. et al., "Rifaximin significantly improves quality of life versus placebo in patients with diarrhea-predominant irritable bowel syndrome", Am. J. Gastroenterology, (20080900), vol. 103, pages S461 - S462, XP055671772

DOI:   http://dx.doi.org/10.14309/00000434-200809001-01182
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.